273 related articles for article (PubMed ID: 1250045)
1. [Immunological aspects of melanoma].
Sjögren H
Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
[No Abstract] [Full Text] [Related]
2. BCG in cancer therapy: theoretical bases of immunotherapy.
Dodd MJ
Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
[No Abstract] [Full Text] [Related]
3. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
[No Abstract] [Full Text] [Related]
4. [Immunotherapy of malignant melanomas].
Macher E
Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
[No Abstract] [Full Text] [Related]
5. Progress of immunotherapy in the treatment of malignant melanoma.
Ariyan S
Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
[No Abstract] [Full Text] [Related]
6. Immunotherapy of melanoma with intralesional BCG.
Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
[No Abstract] [Full Text] [Related]
7. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
[No Abstract] [Full Text] [Related]
8. Immune response and non-specific immunotherapy in melanoma.
El-Domeiri AA
Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
[TBL] [Abstract][Full Text] [Related]
9. Immunological changes in cancer patients receiving BCG.
Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
[TBL] [Abstract][Full Text] [Related]
10. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of melanoma.
Chapman PB
Cancer Chemother Biol Response Modif; 2002; 20():371-83. PubMed ID: 12703215
[No Abstract] [Full Text] [Related]
12. [Immunotherapy].
Lejeune FJ; Bernheim JL; Vanwijck R
Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
[No Abstract] [Full Text] [Related]
13. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in malignant melanomaa.
Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
[TBL] [Abstract][Full Text] [Related]
15. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Peter HH; Deutschmann EM; Schultheis W; Deicher H
Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
[TBL] [Abstract][Full Text] [Related]
16. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
17. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
18. [Immunology of melanoma].
Vanwijck R; Bernheim JL; Lejeune FJ
Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
[No Abstract] [Full Text] [Related]
19. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
[No Abstract] [Full Text] [Related]
20. [Immunologic aspects of the treatment of melanoma].
Pawlowska EM
Pol Tyg Lek; 1977 Jun; 32(24):939-41. PubMed ID: 882435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
